Responses

Download PDFPDF

Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Sjögren’s syndrome with cryoglobulinemic vasculitis – successful treatment with rituximab
    • Shweta S Bhagat, Specialist Registrar
    • Other Contributors:
      • Sumeet Agrawal, Bhaskar Dasgupta

    Dear Editor,

    We read with interest the review on anti CD-20 monoclonal antibody treatment for cryoglobulinemic vasculitis by Cacoub et al. We share our experience with two cases of cryoglobulinemic vasculitis associated with Sjogren’s syndrome which were treated successfully with Rituximab. An 80-year-old man with Sjogren’s syndrome (SS) for 15 years, (anti-Ro/La positive, with peripheral neuropathy and immune thr...

    Show More
    Conflict of Interest:
    None declared.